Navigation Links
RegeneCure Starts Clinical Study Using Polymeric Bone Stimulating Membrane for Dental Implants

JERUSALEM, June 18, 2013 /PRNewswire/ --

RegeneCure announced today the start of a clinical study using the company's  proprietary AMCA Guided Bone Regeneration (GBR) Dental Membrane as a bone stimulating aid for patients requiring dental implants.

A common problem encountered when patients have a tooth replaced with a dental implant is the lack of sufficient bone volume to house the implant. Consequently there is often a need to support the implant with a bone substitute until the natural bone regenerates. The bone substitute material, in turn, needs to be held in place by a membrane.

RegeneCure's innovative AMCA GBR membrane has important quality and safety advantages over currently-used collagen-based membranes:

The membrane is entirely synthetic, eliminating risk of contamination by pathogens present in animal-tissue-derived membranes:

The AMCA GBR membrane is strong, degrades slowly over time, giving the natural bone more time to properly regenerate;

The membrane accelerates healing by enabling excellent cell adherence, proliferation and differentiation of stem cells into the bone tissue, while preventing connective tissue from infiltrating into the healing space.

"Pre-clinical trials have shown excellent healing, including complete restoration of the bone," said Moshe Tzabari, CEO of RegeneCure, adding "Our technology is designed to improve and accelerate healing in a large variety of medical procedures."

About The Trial

A total of 32 patients suffering from insufficient bone volume for dental implant placement will be enrolled in the prospective, randomized, controlled study. One study arm, comprising 16 patients, will use RegeneCure's membrane; the other study arm, also comprising 16 patients, will use a collagen membrane.  Study participants will include non-smokers and smokers, in order to provide clinical data for potential use in both smoking and non-smoking populations.

The study will examine if RegeneCure's membrane enables a similar or better amount of lateral bone fill compared with the collagen membrane which is considered the gold standard treatment today. Each patient will be followed over a 6-month period.

The Principal Investigators are  Prof. Lior Shapira, Chairman of the Department of Periodontology at the Hadassah  Medical Center, Jerusalem, Israel and Prof. Eli Machtei, Director of the  Dept. of Oral Medicine & Periodontology at the Rambam Medical Center in Haifa, Israel.

The AMCA membrane is thin and flexible, drill-able, and easily sutured in the treated area. It is easy to use in orthopedic surgery and requires no special surgical knowledge or special preparation prior to use.

About the Market

The global dental implants market is set to almost double in value over the next six years, owing to the aging population and the availability of advanced solutions for dental implants in conjunction with oral regenerative tissue products. Global sales of dental implant systems reached more than $3.4 billion in 2012 with Europe (49%) as largest market before the United States (31%). In 2012, the global dental membrane market was over $200 million with annual growth of 5-10% to reach $300 million by 2017.

About  RegeneCure

RegeneCure Ltd. was founded in July 2010 to develop, produce and market synthetic implants for bone reconstruction and fracture fusion for the orthopedic, dental and aesthetic fields. AMCA Membrane Implant technology is protected by worldwide patents. The company submitted a 510(k) application to the FDA in April 2012 for an initial trauma indication. The privately owned company has manufacturing facility meeting the high production standards required by European and United States authorities. In 2012, the company received ISO 13485:2003 certification.

For more information visit or contact: Dr. Harry Langbeheim, VP Business Development,, Tel: +972-2-5401013

SOURCE RegeneCure Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Mexican State of Tamaulipas Starts Training Doctors in Sangui Wound Management
2. Lab course that starts with students own ideas wins Science magazine prize
3. Management Matters Series Starts with “Lab Budgeting 101”
4. Week One of All Things Medical Auction Event Starts Monday, March 11, 2013 Conducted by IpAuctions™, Inc.
5. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
6. Positive Clinical Study Results for BSPs HyperQ Technology
7. DermTechs Non-invasive Melanoma Detection Assay Poised to Enter Clinical Validation Study
8. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
9. AtheroNova Inc. Preclinical Study Demonstrates 95% Reduction in Arterial Plaque Formation
10. A New Type of Dendritic Cell-Based Cancer Vaccine has Received Approval for Clinical Tests and at the Same Time Secures Substantial Financing
11. Generex Provides Update on Generex Oral-lyn™ Clinical & Regulatory Program
Post Your Comments:
(Date:11/25/2015)... , November 26, 2015 ... Global Biobanking Market 2016 - 2020 report analyzes ... maintaining integrity and quality in long-term samples, minimizing ... long-term cost-effectiveness. Automation minimizes manual errors such as ... technical efficiency. Further, it plays a vital role ...
(Date:11/25/2015)... 2 nouvelles études permettent d , identifier ... souches bactériennes retrouvées dans la plaque dentaire des ... Ces recherches  ouvrent une nouvelle voie ... l,un des problèmes de santé les plus fréquemm ... --> 2 nouvelles études permettent d , ...
(Date:11/25/2015)... HOLLISTON, Mass. , Nov. 25, 2015 /PRNewswire/ ... ), a biotechnology company developing bioengineered organ implants for ... will present at the LD Micro "Main Event" ... p.m. PT. The presentation will be webcast live and ... will also be available at the conference for one-on-one ...
(Date:11/25/2015)... 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS; TSX: ... prospects remain fundamentally strong and highlights the following ... received DSMB recommendation to continue the ZoptEC Phase ... the final interim efficacy and safety data ... men with heavily pretreated castration- and Taxane-resistant prostate ...
Breaking Biology Technology:
(Date:11/16/2015)... Nov 16, 2015  Synaptics Inc. (NASDAQ: ... solutions, today announced expansion of its TDDI product ... touch controller and display driver integration (TDDI) solutions ... These new TDDI products add to the previously-announced ... TD4302 (WQHD resolution), and TD4322 (FHD resolution) solutions. ...
(Date:11/11/2015)... MINNETONKA, Minn. , Nov. 11, 2015   MedNet ... the entire spectrum of clinical research, is pleased to announce ... Partnerships in Clinical Trials (PCT) event, to be held ... will be able to view live demonstrations of ... platform, and learn how iMedNet has been able ...
(Date:11/9/2015)... 9, 2015  Synaptics Inc. (NASDAQ: SYNA ), ... broader entry into the automotive market with a comprehensive ... pace of consumer electronics human interface innovation. Synaptics, industry-leading ... for the automotive industry and will be implemented in ... Europe , Japan , and ...
Breaking Biology News(10 mins):